These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 22891628)

  • 1. Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?
    Teich AF; Arancio O
    Biochem J; 2012 Sep; 446(2):165-77. PubMed ID: 22891628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
    Fischer A
    Neuropharmacology; 2014 May; 80():95-102. PubMed ID: 24486385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.
    Herrup K; Carrillo MC; Schenk D; Cacace A; Desanti S; Fremeau R; Bhat R; Glicksman M; May P; Swerdlow R; Van Eldik LJ; Bain LJ; Budd S
    Alzheimers Dement; 2013 Jul; 9(4):452-458.e1. PubMed ID: 23809366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β Receptors: The Good, the Bad, and the Prion Protein.
    Jarosz-Griffiths HH; Noble E; Rushworth JV; Hooper NM
    J Biol Chem; 2016 Feb; 291(7):3174-83. PubMed ID: 26719327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
    Dunys J; Valverde A; Checler F
    J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?
    Panza F; Lozupone M; Bellomo A; Imbimbo BP
    Ageing Res Rev; 2019 Nov; 55():100948. PubMed ID: 31454563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facilitation of brain mitochondrial activity by 5-aminolevulinic acid in a mouse model of Alzheimer's disease.
    Omori C; Motodate R; Shiraki Y; Chiba K; Sobu Y; Kimura A; Nakaya T; Kondo H; Kurumiya S; Tanaka T; Yamamoto K; Nakajima M; Suzuki T; Hata S
    Nutr Neurosci; 2017 Nov; 20(9):538-546. PubMed ID: 27329428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
    Parnetti L; Senin U; Mecocci P
    Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy.
    Harkany T; Abrahám I; Kónya C; Nyakas C; Zarándi M; Penke B; Luiten PG
    Rev Neurosci; 2000; 11(4):329-82. PubMed ID: 11065280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies.
    Hölscher C
    Rev Neurosci; 2005; 16(3):181-212. PubMed ID: 16323560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies.
    Vijayan D; Chandra R
    Curr Drug Targets; 2020; 21(2):148-166. PubMed ID: 31385768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward an early diagnosis and treatment of Alzheimer's disease.
    Nordberg A
    Int Psychogeriatr; 2003 Sep; 15(3):223-37. PubMed ID: 14756159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to the treatment of Alzheimer's disease.
    Rampa A; Bisi A
    Curr Top Med Chem; 2013; 13(15):1743-4. PubMed ID: 23931444
    [No Abstract]   [Full Text] [Related]  

  • 16. Disease modifying drugs targeting β-amyloid.
    Ozudogru SN; Lippa CF
    Am J Alzheimers Dis Other Demen; 2012 Aug; 27(5):296-300. PubMed ID: 22815077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.
    Pham E; Crews L; Ubhi K; Hansen L; Adame A; Cartier A; Salmon D; Galasko D; Michael S; Savas JN; Yates JR; Glabe C; Masliah E
    FEBS J; 2010 Jul; 277(14):3051-67. PubMed ID: 20573181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease.
    De Felice FG; Ferreira ST
    Cell Mol Neurobiol; 2002 Dec; 22(5-6):545-63. PubMed ID: 12585679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of aricept with a traditional Chinese medicine formula, smart soup, may be a novel way to treat Alzheimer's disease.
    Wang Y; Wang Y; Sui Y; Yu H; Shen X; Chen S; Pei G; Zhao J; Ding J
    J Alzheimers Dis; 2015; 45(4):1185-95. PubMed ID: 25690664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.